Studies have demonstrated that inflammatory mediators such as fractalkine/CX3CL1, CCL8, M-CSF, HGF, E-selectin, PI3/elafin, CCL17, and IL-16 are significantly elevated in patients with AD, contributing to the progression of arteriosclerosis (43–45). This evidence concerns the gene CCL17 and Alzheimer disease.